US 12,275,796 B2
Interferon-associated antigen binding proteins and uses thereof
Antoine Alam, Lyons (FR)
Assigned to EVOTEC INTERNATIONAL GmbH, Hamburg (DE); and SANOFI, Paris (FR)
Filed by EVOTEC INTERNATIONAL GmbH, Hamburg (DE); and SANOFI, Paris (FR)
Filed on Jan. 11, 2023, as Appl. No. 18/152,969.
Application 18/152,969 is a continuation of application No. 17/756,803, previously published as PCT/EP2020/083745, filed on Nov. 27, 2020.
Claims priority of application No. 19306552 (EP), filed on Dec. 3, 2019; and application No. 19306573 (EP), filed on Dec. 4, 2019.
Prior Publication US 2023/0279137 A1, Sep. 7, 2023
Int. Cl. A61K 39/395 (2006.01); A61K 38/21 (2006.01); A61P 31/20 (2006.01); C07K 14/555 (2006.01); C07K 16/28 (2006.01); C12N 15/63 (2006.01)
CPC C07K 16/2878 (2013.01) [A61P 31/20 (2018.01); C07K 14/555 (2013.01); C12N 15/63 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2319/33 (2013.01)] 31 Claims
OG exemplary drawing
 
1. A pharmaceutical composition comprising an interferon-associated antigen binding protein comprising:
(I) an agonistic anti-CD40 antibody or an agonistic antigen binding fragment thereof, fused to (II) an Interferon-α2a (IFNα2a) or a functional fragment thereof, optionally fused via a linker, wherein the functional fragment mediates interferon pathway signaling,
wherein the agonistic anti-CD40 antibody, or the agonistic antigen binding fragment thereof, comprises a heavy chain or a fragment thereof and a light chain or a fragment thereof,
wherein the heavy chain or the fragment thereof comprises a complementarity determining region 1 (CDRH1) comprising the amino acid sequence of SEQ ID NO: 56; a complementarity determining region 2 (CDRH2) comprising the amino acid sequence of SEQ ID NO: 57; and a complementarity determining region 3 (CDRH3) comprising the amino acid sequence of SEQ ID NO: 58; and
wherein the light chain or the fragment thereof comprises a complementarity determining region 1 (CDRL1) comprising the amino acid sequence of SEQ ID NO: 52; a complementarity determining region 2 (CDRL2) comprising the amino acid sequence of SEQ ID NO: 53; and a complementarity determining region 3 (CDRL3) comprising the amino acid sequence of SEQ ID NO: 54.